Abstract: The present invention refers to human antibodies which are directed against ?-Synuclein (?-Syn) and their use in medicine and diagnosis.

Abstract: The present invention refers to human antibodies which are directed against ?-Synuclein (?-Syn) and their use in medicine and diagnosis.

Abstract: Isolated, monoclonal, human, anti-?-amyloid antibodies are provided which bind to dimeric forms of Ab with higher affinity than to monomeric forms of Ab and when bound to an A? polypeptide comprising A?(21-37) shield A?(21-37) from proteolytic digestion. The antibodies were shown to inhibit fibril formulation and reduce plaque size in vivo and to not bind brain vessel walls. Accordingly, the antibodies are useful in human and veterinary medicine for the treatment and prophylaxis of Alzheimer's disease and other neurodementing diseases. Methods of detecting or measuring the progression of a neurodementing disease also are provided.

Abstract: A method, particularly an enzyme-linked immunosorbent assay (ELISA), for the in-vitro detection of A? autoantibodies in human serum and/or plasma contains the following steps: preparing an antigen-coated solid phase; incubating the solid phase with a blocking solution; incubating the solid phase with a sample to be examined; immunological detection of the A? autoantibodies on the solid phase; and reading the detected results of the solid phase using a reading tool. According to the invention, the preparation of the antigen-coated solid phase advantageously includes incubating the solid phase with a coating solution in which the antigen is dissolved, said antigen having a peptide sequence selected from the group SEQ ID No. 1, SEQ ID No. 2 or SEQ ID No. 3.

Abstract: The present invention refers to human antibodies which are directed against ?-Synuclein (?-Syn) and their use in medicine and diagnosis.

Abstract: Isolated, monoclonal, human, anti-?-amyloid antibodies are provided which bind to dimeric forms of Ab with higher affinity than to monomeric forms of Ab and when bound to an A? polypeptide comprising A?(21-37) shield A?(21-37) from proteolytic digestion. The antibodies were shown to inhibit fibril formulation and reduce plaque size in vivo and to not bind brain vessel walls. Accordingly, the antibodies are useful in human and veterinary medicine for the treatment and prophylaxis of Alzheimer's disease and other neurodementing diseases. Methods of detecting or measuring the progression of a neurodementing disease also are provided.

Abstract: Isolated, monoclonal, human, anti-?-amyloid antibodies are provided which bind to dimeric forms of Ab with higher affinity than to monomeric forms of Ab and when bound to an A? polypeptide comprising A?(21-37) shield A?(21-37) from proteolytic digestion. The antibodies were shown to inhibit fibril formation and reduce plaque size in vivo and to not bind brain vessel walls. Accordingly, the antibodies are useful in human and veterinary medicine for the treatment and prophylaxis of Alzheimer's disease and other neurodementing diseases. Methods of detecting or measuring the progression of a neurodementing disease also are provided.

Abstract: Isolated, monoclonal, human, anti-?-amyloid antibodies are provided which bind to dimeric forms of Ab with higher affinity than to monomeric forms of Ab and when bound to an A? polypeptide comprising A?(21-37) shield A?(21-37) from proteolytic digestion. The antibodies were shown to inhibit fibril formation and reduce plaque size in vivo and to not bind brain vessel walls. Accordingly, the antibodies are useful in human and veterinary medicine for the treatment and prophylaxis of Alzheimer's disease and other neurodementing diseases. Methods of detecting or measuring the progression of a neurodementing disease also are provided.

Abstract: Isolated, monoclonal, human, anti-?-amyloid antibodies are provided which bind to dimeric forms of Ab with higher affinity than to monomeric forms of Ab and when bound to an A? polypeptide comprising A?(21-37) shield A?(21-37) from proteolytic digestion. The antibodies were shown to inhibit fibril formation and reduce plaque size in vivo and to not bind brain vessel walls. Accordingly, the antibodies are useful in human and veterinary medicine for the treatment and prophylaxis of Alzheimer's disease and other neurodementing diseases. Methods of detecting or measuring the progression of a neurodementing disease also are provided.

Abstract: As discussed above the present invention in a first aspect thereof relates to the use of a tetracycline, preferably minocycline, for manufacture of a pharmaceutical composition for treatment or prevention of a disorder selected from Parkinson's disease and related disorders, preferably Parkinson's disease.

Abstract: The present invention provides according to the first aspect thereof a human anti-&bgr;-amyloid antibody obtained by purification from a human IgG-containing bodyfluid by A&bgr;-affinity chromatography. In a second aspect the invention provides a method of purification of an anti-A&bgr;-amyloid antibody, said method comprising the steps of obtaining a human IgG-containing bodyfluid, subjecting the bodyfluid obtained to an A&bgr;-affinity chromatography, and recovering the purified anti-A&bgr; antibody from the chromatography medium. Finally the invention provides for use of the above anti-A&bgr; antibody for diagnosing and/or treating amyloid associated diseases, especially Alzheimer's disease and for a pharmaceutical composition comprising said antibody for treatment of Alzheimer's disease.